XTX Topco Ltd Acquires 225,823 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)

XTX Topco Ltd lifted its position in Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 186.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 347,255 shares of the company's stock after purchasing an additional 225,823 shares during the quarter. XTX Topco Ltd owned about 0.28% of Mersana Therapeutics worth $656,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. US Bancorp DE purchased a new position in Mersana Therapeutics in the third quarter worth $31,000. Dynamic Technology Lab Private Ltd purchased a new stake in Mersana Therapeutics during the third quarter valued at about $34,000. Intech Investment Management LLC purchased a new stake in Mersana Therapeutics during the third quarter valued at about $52,000. Quarry LP purchased a new stake in Mersana Therapeutics during the third quarter valued at about $57,000. Finally, Algert Global LLC purchased a new stake in shares of Mersana Therapeutics during the second quarter worth about $90,000. Institutional investors own 93.92% of the company's stock.

Mersana Therapeutics Price Performance

MRSN stock traded down $0.15 during mid-day trading on Friday, hitting $2.15. The company had a trading volume of 886,843 shares, compared to its average volume of 1,573,243. The company has a 50-day moving average price of $2.17 and a 200 day moving average price of $1.98. Mersana Therapeutics, Inc. has a 12-month low of $1.22 and a 12-month high of $6.28. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. The company has a market capitalization of $265.59 million, a price-to-earnings ratio of -3.51 and a beta of 1.40.

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last posted its earnings results on Wednesday, November 13th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The firm had revenue of $12.60 million for the quarter, compared to the consensus estimate of $7.53 million. During the same period in the previous year, the firm posted ($0.35) EPS. The business's quarterly revenue was up 63.6% on a year-over-year basis. On average, research analysts anticipate that Mersana Therapeutics, Inc. will post -0.61 earnings per share for the current year.

Analyst Ratings Changes

Separately, Citigroup assumed coverage on shares of Mersana Therapeutics in a research note on Friday, November 15th. They issued a "buy" rating and a $5.00 price target for the company. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Mersana Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $6.00.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.